BMS’ neuro renaissance was built on back of Celgene mega-merger

▤ Summary

Bristol Myers Squibb is expanding its neuroscience business and tying that growth to its 2019 Celgene merger. The company now has a broader pipeline in Alzheimer’s disease, multiple sclerosis, and psychiatric conditions, with Cobenfy serving as an anchor asset. It also continues to advance later-stage and early-stage programs, including irafamdastat, moponetug, and brain-shuttle technologies. The article highlights how biomarkers, genetics, and delivery platforms are improving the outlook for neuroscience drug development.

▦ Linked Companies

Roche

$1B+